• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

GE Healthcare, Blue Earth Diagnostics ink UK manufacturing deal

October 3, 2017 By Sarah Faulkner

Blue Earth DiagnosticsBlue Earth Diagnostics and GE Healthcare (NYSE:GE) said today that the group has inked a deal to establish the manufacturing of Blue Earth Diagnostic’s positron emission tomography imaging product, Axumin, in the U.K.

The agreement with GE Healthcare is part of Blue Earth Diagnostics’ move towards commercializing Axumin since it won marketing authorization from the European Commission in May this year.

Axumin is designed to be used in PET imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated prostate specific antigen levels following primary curative treatment, the company reported.

“This agreement with GE Healthcare marks the first step towards full commercial availability of Axumin in the UK.,” Blue Earth Diagnostics’ CEO Jonathan Allis said in prepared remarks.

“Detection and localization of recurrent prostate cancer is a significant unmet medical need, and Blue Earth Diagnostics is committed to making Axumin accessible to clinicians and their patients across Europe. Today’s announcement is another step towards that goal, and we look forward to working with the team at GE.”

“We are thrilled to support Blue Earth Diagnostics in their mission to improve prostate cancer care for patients in the UK,” Kevin O’Neill, GM of GE Healthcare Life Sciences’ core imaging business, added. “We are very excited to contribute to this project with the expertise, quality and reliability of GE Healthcare’s PET production capabilities in the UK.”

Filed Under: Diagnostics, Featured, Imaging, Oncology Tagged With: blueearthdiagnostics, GE Healthcare

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS